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Early antipsychotic treatment in childhood/adolescent period has longterm effects on depressive-like, anxiety-like and locomotor behaviours in
adult rats
Abstract

Childhood/adolescent antipsychotic drug (APD) use is exponentially increasing worldwide, despite limited
knowledge of the long-term effects of early APD treatment. Whilst investigations have found that early
treatment has resulted in some alterations to dopamine and serotonin neurotransmission systems (essential to
APD efficacy), there have only been limited studies into potential long-term behavioural changes. This study,
using an animal model for childhood/adolescent APD treatment, investigated the long-term effects of
aripiprazole, olanzapine and risperidone on adult behaviours of male and female rats. Open-field/holeboard,
elevated plus maze (EPM), social interaction and forced swim (FS) tests were then conducted in adult rats.
Our results indicated that in the male cohort, early risperidone and olanzapine treatment elicited long-term
hyper-locomotor effects (open-field/holeboard and FS tests), whilst a decrease in depressive-like behaviour
(in FS test) was observed in response to olanzapine treatment. Furthermore, anxiolytic-like behaviours were
found following testing in the open-field/holeboard and EPM in response to all three drug treatments. Effects
in the female cohort, however, were to a far lesser extent, with behavioural attributes indicative of an increased
depressive-like behaviour and hypo-locomotor activity exhibited in the FS test following early risperidone and
olanzapine treatment. These results suggest that various APDs have different long-term effects on the
behaviours of adult rats.
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Abstract
Childhood/adolescent antipsychotic drug (APD) use is exponentially increasing worldwide,
despite limited knowledge of the long-term effects of early APD treatment. Whilst
investigations have found that early treatment has resulted in some alterations to dopamine
and serotonin neurotransmission systems (essential to APD efficacy), limited studies into
potential long-term behavioural changes have occurred. This study, using an animal model
for childhood/adolescent APD treatment, investigated the long-term effects of Aripiprazole,
Olanzapine and Risperidone on adult behaviours of male and female rats. Openfield/holeboard, elevated plus maze (EPM), social interaction and forced swim (FS) tests
were then conducted in adult rats. Our results indicated that in the male cohort, early
Risperidone and Olanzapine treatment elicited long-term hyper-locomotor effects (openfield/holeboard and FS tests), whilst a decrease in depressive-like behaviour (in FS test) was
observed in response to Olanzapine treatment. Furthermore, anxiolytic-like behaviours were
found following testing in the open-field/holeboard and EPM in response to all 3 drug
treatments. Effects in the female cohort however were to a far lesser extent, with behavioural
attributes indicative of an increased depressive-like behaviour and hypo-locomotor activity
were exhibited in the FS test following early Risperidone and Olanzapine treatment. These
results suggest that various APDs have different long-term effects on the behaviours of adult
rats.

Keywords: Antipsychotic drug, Risperidone, Olanzapine, Motor activity, Anxiety,
Depression, Development.

2

Abbreviations

5-HT, Serotonin
ANOVA, Analysis of Variance
APD, Antipsychotic Drug
DA, Dopamine
EPM, Elevated Plus Maze
FS, Forced Swim
NT, Neurotransmitter
PD, Postnatal Day
SEM, Standard Error of the Mean
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1. Introduction
The use of antipsychotic drugs (APDs) in children and adolescents is rapidly increasing
worldwide, despite serious limitation in the safety and efficacy of APD use in these
population groups (Rani et al. 2008; Varley and McClellan 2009; Olfson et al. 2010;
Alexander et al. 2011; Olfson et al. 2012; Seida et al. 2012; Hoekstra 2014). Whilst firstgeneration APDs (e.g. Haloperidol and Chlorpromazine) are used less frequently in children
and adolescence due to their serious extrapyramidal side-effects, second-generation APDs
including Aripiprazole, Olanzapine and Risperidone are commonly prescribed (mostly offlabel) for treating various childhood disorders; from mental illnesses including anxiety,
depression and child-onset schizophrenia (Olfson et al. 2010; Memarzia et al. 2014;
Schneider et al. 2014), to various behavioural disorders (Haw and Stubbs 2007; Vitiello et al.
2009; Sharma and Shaw 2012). Whilst the therapeutic effects of APDs are predominantly
based on their antagonist or partial agonist mechanisms of action on the dopamine (DA) D2
and serotonin (5-HT) 5-HT1A and 5-HT2A/2C receptors (Meltzer 2002; Meltzer et al. 2003;
Grace et al. 2007; Kegeles et al. 2010; Purves-Tyson et al. 2012; Milstein et al. 2013), the
dopaminergic and serotonergic neurotransmitter (NT) systems are also heavily involved in
multiple neurodevelopmental processes during the childhood/adolescent period (Levitt et al.
1997; Frost and Cadet 2000; Andersen 2003; Klomp et al. 2012; Milstein et al. 2013). There
is therefore the potential for APD use in such a critical neurodevelopmental time period to
carry a substantial risk of long-term behavioural pathologies, due to their potent actions on
the still developing DA and 5-HT NT systems (Andersen 2003; Andersen and Navalta 2004;
Andersen 2005; Vinish et al. 2012; Memarzia et al. 2014).
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Although current clinical research into the use of APDs in the adolescent population over
both a short term period of between 1-2 months, and longer-term period of up to 6 months
has found some benefits in the treatment of some mental illness symptomology (Stigler et al.
2004; Kumra et al. 2008; Zuddas et al. 2011), there is limited data on the potential for longterm alterations to adult behaviours (Milstein et al. 2013; Shu et al. 2014; Varela et al. 2014).
Although the effects of childhood/adolescent APD use on adult behaviours is unknown in a
clinical setting, current animal studies have shown that early drug treatment for a period of up
to 4 weeks can result in various significant alterations in the dopaminergic and serotonergic
pathways in the brain long-term (Maciag et al. 2006; Moran-Gates et al. 2006; Vinish et al.
2012; Milstein et al. 2013; Memarzia et al. 2014; Varela et al. 2014), including permanent
changes in the distribution of NT receptors and dendritic architecture (Maciag et al. 2006;
Moran-Gates et al. 2006; Milstein et al. 2013), with minimal evidence of the direct effects on
behaviour. Alterations to the production, transport and binding of DA and 5-HT in the
cortical and striatal brain regions have already been directly linked to changes in behavioural
attributes, including locomotor activity levels along with depressive-like and anxiety-like
behaviours. The present study therefore investigated the long-term effects of APD treatment
during the critical neurodevelopmental window of childhood/adolescence, on behavioural
attributes in adult rats, including locomotor activity, depressive-like, anxiety-like, exploratory
and social behaviours.

2. Materials and Methods
2.1. Animals and Housing
Timed pregnant Sprague-Dawley rats were obtained at gestation day 16 from the Animal
Resource Centre (Perth, WA, Australia). They were housed in individual cages under
5

environmentally controlled conditions (22°C, light cycle from 07:00 to 19:00 and dark cycle
from 19:00 to 07:00), and allowed ad libitum access to water and standard laboratory chow
diet (3.9 kcal/g: 10% fat, 74% carbohydrate, 16% protein). Day of birth was considered
postnatal day (PD) 0. Pups were sexed on PD14, and then 96 Sprague-Dawley rats (48 male
and 48 female) were weaned on PD20 and housed in individual cages. All experimental
procedures were approved by the Animal Ethics Committee, University of Wollongong,
NSW, Australia (AE 12/20), and complied with Australian Code of Practice for the Care and
Use of Animals for Scientific Purpose (2004).

2.2. Drug Treatment Groups
Before the drug treatment commenced, the rats were trained for self-administration by
feeding them cookie dough (0.3 g) without drugs 2 times per day for PD 18-21. Animals were
then assigned randomly to one of four experimental groups per gender on PD21 (n =
12/group): (1) Aripiprazole (Otsuka, Japan), (2) Olanzapine (Eli Lilly, USA), (3) Risperidone
(Apotex, Canada), or (4) control (vehicle). The drug treatment period from PD22-50 in the
rats was carried out at the equivalent time of the childhood/periadolescent phase in
humans(Andersen 2003). A staggered drug treatment pattern, where lower APD dosages are
slowly increased to a final dosage amount, was used to mimic a clinical setting(Taylor et al.
2009). The APD doses were initiated on PD22 at 0.2 mg/kg, 3 times per day for Aripiprazole;
0.25 mg/kg, 3 times per day for Olanzapine; and 0.05 mg/kg, 3 times per day for Risperidone,
and then increased in 3 steps over the first 7 days of the 4 week treatment period to achieve a
final dose on PD28 of 1 mg/kg, 3 times per day for Aripiprazole, 1 mg/kg, 3 times per day for
Olanzapine, and 0.3 mg/kg, 3 times per day for Risperidone. The proposed dosages are within
the recommended dosage ranges for the psychiatric treatment of paediatric patients, based on
the body surface area formula for dosage translation between humans and rats in the FDA
6

guideline for clinical trials (Food & Drug Administration 2005; Reagan-Shaw et al. 2008;
Taylor et al. 2009; Zuddas et al. 2011). It has been previously reported that, at these used
dosages, Aripiprazole drug treatment reaches above 90% DA D2 receptor occupancy rates in
the rat brain (Wadenberg 2007), while Olanzapine and Risperidone reach 65-80% DA D2
receptor occupancy (Kapur et al. 2003; Natesan et al. 2006). These dosages have also been
shown to be physiologically and behaviourally effective in our laboratory, with similar
dosages seen to induce weight gain and changes in hypothalamic neuropeptide Y expression
in adolescent rats (Lian et al. 2015), whilst alterations to both DA and 5-HT receptor binding
has been reported in adult rats (Han et al. 2009; Weston-Green et al. 2011). The 0.3 g dry
cookie dough pellets were fed to the rats 3 times per day (07:00h, 14:00h and 22:00h; with
8±1 hour intervals) over the 4 week treatment period. Rats were observed throughout the
treatment to ensure that they completely consumed the cookie dough pellet. The rats in the
control group received an equivalent pellet without the drug.

2.3. Behavioural Tests
All behavioural tests were carried out between 09:00 and 17:00h. All protocols for the
behavioural tests used in the present study were adapted from previous studies (Burne et al.
2004; du Bois et al. 2008). Behavioural tests were carried out over a 4 week period from
PD72-94 (the equivalent of adulthood) in the following sequence; open-field/holeboard test,
elevated plus maze test, social interaction test, and forced swim test, as described below.

2.3.1. Open-Field/Holeboard Test
The open-field/holeboard test was modified from previous designs and carried out on PD72
to examine exploratory behaviour and locomotor activity (Burne et al. 2004; du Bois et al.
2008). A single rat was placed in a black square arena (60cm x 60cm x 40cm), with a
floorboard insert placed 5cm above the base, with four holes, 5cm in diameter, each situated
7

10cm in from each of the corners. The light intensity was 30lx across the entire arena. Rat
behaviour was recorded with a centrally located video camera for 30 minutes. Locomotor
activity was later analysed using video-tracking software (Noldus Information Technology,
Wageningen, The Netherlands). The frequency of head dips were scored manually.

2.3.2. Elevated Plus Maze
The elevated plus maze test was modified from previous designs and carried out on PD79, to
examine anxiety-like behaviours and locomotor activity (Wigger and Neumann 1999; Burne
et al. 2004; Mällo et al. 2007; du Bois et al. 2008). It consisted of two open arms (50cm x
7cm) and two closed arms (50cm x 7cm x 30cm) with an open roof, arranged around a central
platform (7cm x 7cm). Like-arms opposed each other across the central platform. The maze
was a wooden structure, painted with a black acrylic, and elevated 60cm above the floor. The
light intensity was set at 100 lx at the open arms and central platform. A single rat was placed
on the central platform facing an open arm and rat behaviour was recorded for 7 minutes with
a centrally located video camera. We measured the number of open and closed arm entries,
and the duration of time spent in the open and closed arms, central platform and ‘open part’
(open arms plus central platform). We also measured the number of arm changes as a
measure of general locomotor activity on the maze. Data was scored manually, with criterion
for entry into the open/closed arms was whole body and four paws entry; a

rat was

considered to be in the central platform zone if its head and front paws were in the central
platform, with its body positioned in the closed arm.

2.3.3. Social Interaction
The social interaction test was modified from previous designs and was carried out on PD86
to examine social and anxiolytic behaviours (Burne et al. 2004; du Bois et al. 2008). It was
performed in a black circular arena (90cm diameter x 30cm high walls) made of a black
acrylic, with light intensity at 30 lx across the entire arena. Two unfamiliar rats of a similar
8

size, of the same sex and from the same treatment group were placed on opposing sides of the
arena, allowed to move around freely and behaviour was recorded for 7 minutes with a
centrally located video camera. All rats were only tested once. Behaviour was analysed via
the use of video-tracking software (Noldus Information Technology, Wageningen, The
Netherlands) looking at time spent within a given proximity (set at 20cm – average body
length) of one another, and mean distance between each other, and gathered data from each
Social Interaction test involving two rats was analysed as a single data point. No aggressive
behaviours were observed using this procedure.

2.3.4. Forced Swim Test
The forced swim test was modified from previous designs and was carried out on PD93 and
94 to examine depressive-like behaviours and locomotor activity (Burne et al. 2004; du Bois
et al. 2008). A blue opaque cylinder (30cm x 50cm) was filled to predetermined water level
(30°C), dependent upon the body length of each individual rat. Rats were measured from the
tip of the snout to the base of the tail, and water depth was then calculated by multiplying this
value by 1.25. Rats were tested over 2 days, at a light intensity of 1000 lx (fluorescence strip
lighting-stress conditions). On the first day, the rats were placed in the water for a 10 minute
duration, then removed and dried with towels and placed in a cage with paper towel for 20
minutes prior to being returned to their home cages. Water was changed between rats. On the
second day, the rats were placed in the cylinder for a period of 5 minutes. Locomotor activity
was recorded on the second day using a centrally located video camera. We manually
evaluated the time spent climbing (defined as vertical movements of the forepaws, usually up
against the cylinder), swimming (movement throughout the cylinder, usually in a horizontal
direction), and floating (immobile – an absence of movement except for that required to keep
its head above water).
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2.4. Statistical Analysis
All collected data were analysed using SPSS software (Windows version 19.0, SPSS Inc.,
Chicago, IL, USA). The Kolmogorov-Smirnov test was used to examine the distribution of
data from all experiments. All normally distributed data from male and female rats were also
analysed by two-way analysis of variances (ANOVAs) (Gender x Treatment). Then data
from males or females were analysed separately by one-way ANOVA, followed by post-hoc
Tukey tests for multiple comparisons between the treatment groups. Due to the interrelationship of activity levels, we also utilized an analysis of covariance (ANCOVA) test with
total distance travelled (cm) obtained in Open Field/Hole Board test as the co-variate factor to
further analyse data from Elevated Plus Maze and Forced Swim Tests. Data that was not
normally distributed was analysed via the non-parametric Mann-Whitney U-test. All data
were expressed as mean ± standard error of the mean (±SEM), and statistical significance
was accepted when p ≤ 0.05.

3. Results
Following a childhood/adolescent treatment of Aripiprazole, Olanzapine, Risperidone or
vehicle for 4 weeks (PD22-50), a series of 4 behavioural tests including the OpenField/Holeboard, Elevated-Plus Maze (EPM) and Social Interaction and Forced Swim (FS)
tests, were conducted over a 4 week period (PD72-94).

3.1. Open Field/Holeboard
Two-way ANOVAs (Gender x Treatment) revealed significant effects of Gender on average
velocity (F1,90 = 49.780, p < 0.001), total distance moved (F1,90 = 32.838, p < 0.001) and
rearing (F1,90 = 17.028, p < 0.001), along with a significant interaction between the two
factors on total distance moved (F3,90 = 2.772, p < 0.05). Analyses revealed that female rats
10

had a higher locomotor activity level compared to male rats (p < 0.05), and furthermore, male
and female rats were also found to respond differently to early APD treatment (Table 1). In
male rats, a significant effect of treatment on average velocity (F3,46 = 4.473, p < 0.01), total
distance moved (F3,46 = 5.115, p < 0.01) and a trend to significance with rearing (F3,45 =
2.685, p = 0.059) were found. Early Risperidone treatment increased total distance moved
(+32%, p < 0.01), average velocity (+33%, p < 0.01) and rearing (+49%, p < 0.05) (Table 1).
These increases in average velocity, total distance moved and rearing indicated that male rats
treated with Risperidone in the childhood/adolescent period (PD22-50) exhibit hyper–
locomotor activity levels following Open-Field/Holeboard behavioural testing in adulthood
(PD72)(Figure 1). However, no alterations in locomotor activity were observed in the female
treatment groups, indicating that early APD treatment has a stronger long-term effect on the
male cohort.
Figure 1. Behavioural Effects - Activity Levels (A) Male Open Field/Holeboard Distance Travelled (cm); (B)
Female Open Field/Holeboard Distance Travelled (cm) in Sprague-Dawley rats treated chronically with
Aripiprazole (1.0 mg/kg, t.i.d), Olanzapine (1.0 mg/kg, t.i.d), Risperidone (0.3 mg/kg, t.i.d) or control (vehicle).
Data expressed as mean ± SEM. **, p < 0.01 vs. control. Abbreviations: t.i.d.: three times daily.
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Table 1. Behaviour of Male & Female Sprague-Dawley rats treated with chronic treatment of
Aripiprazole (1.0 mg/kg, t.i.d.), Olanzapine (1.0 mg/kg, t.i.d.), Risperidone (0.3
mg/kg, t.i.d.) in the Open-Field/Holeboard tests.
Control

Aripiprazole

Olanzapine

Risperidone

8672.2 ±
705.8

9902.1 ±308.6

9607.6 ±
378.3

11461.6 ±
567.8**

5.2 ± 0.5

6.24 ± 0.3

5.7 ± 0.2

6.8 ± 0.4**

105.2 ±
14.9

145.4 ± 11.9

140.9 ± 10.3

156.5 ± 15.2*

43.6 ± 2.4

48.3 ± 2.4

40.9 ± 1.2

46.85 ± 2.7

353.1 ±
53.6

445.2 ± 65.8

449.6 ± 84.0

401.6 ± 44.1

1384.4 ±
58.8

1303.9 ± 61.6

1298.9 ± 82.7

1248.2 ±
110.4

90.5 ± 11.1

112.6 ± 10.8

104.0 ± 10.3

118.8 ± 7.3

115.6 ±
14.2

135.4 ± 8.9

131.5 ± 10.4

147.8 ± 11.0

11863.9 ±
432.7

12194.5 ±
589.2

12848.1 ±
716.7

11835.4 ±
514.7

7.2 ± 0.2

7.7 ± 0.5

7.9 ± 0.5

8.7 ± 0.4

162.1 ± 9.4

202.2 ± 21.9

209.4 ± 13.0

208.9 ± 16.6

55.4 ± 3.1

59.3 ± 3.3

58.3 ± 3.4

44.4 ± 4.1

Male
Total Distance
Travelled (cm)

Average Velocity
(cm/s)
Rearing Frequency

Head Dips

Centre Duration
(s)

Periphery
Duration (s)
Centre Frequency

Periphery
Frequency

Female
Total Distance
Travelled (cm)

Average Velocity
(cm/s)
Rearing Frequency

Head Dips
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Centre Duration
(s)

227.2 ±
20.0

357.5 ± 62.4

312.4 ± 28.9

310.7 ± 41.3

1465.3 ±
18.9

1333.2 ± 61.8

1383.8 ± 30.4

1396.2 ± 40.0

85.8 ± 6.9

110.7 ± 15.6

113.8 ± 11.3

116.9 ± 15.3

152.5 ± 8.5

184.2 ± 20.0

189.1 ± 17.1

178.7 ± 23.1

Periphery
Duration (s)

Centre Frequency

Periphery
Frequency

Data are expressed as mean ± SEM. * p ≤ 0.05 vs control; ** p < 0.01vs control; *** p
< 0.001 vs control.

3.2. Elevated Plus Maze
Analyses of EPM behavioural data once again revealed that male and female rats were found
to respond differently to early APD treatment (Table 2). Two-way ANOVAs (Gender x
Treatment) revealed significant interaction between Treatment and Gender on centre duration
(F3,85 = 4.023, p < 0.02) and closed arm duration (F3,85 = 5.149, p < 0.01). In male rats,
analysis via ANCOVA of closed arm changes data found a significant effect of Total
Distance Travelled (F1,46 = 8.403, p < 0.01), whilst one-way ANOVA found that early APD
treatment significantly affected centre duration (F3,45 = 8.924, p < 0.001), closed arm duration
(F3,45 = 7.303, p < 0.001) and open part duration (F3,45 = 7.303, p < 0.001) (Table 2). Early
Aripiprazole (+26%, p < 0.001), Olanzapine (+27%, p < 0.05) and Risperidone (+14%, p <
0.01) treatment also increased centre duration compared to the control group. Furthermore,
early Aripiprazole (+53%, p < 0.001) and Risperidone (+30%, p = 0.05) treatment was found
to significantly increase time spent in the open part (open arms + centre platform), with a
similar trend also found in the early Olanzapine (+29%, p = 0.082) treatment group compared
13

to the control. There were reduced closed arm durations following the early Aripiprazole (26%, p < 0.001) and Risperidone (-14%, p = 0.05) treatments, whilst the early Olanzapine (14%, p = 0.082) treatment resulted in a similar trend (Table 2) (Figure 2). However, there
were no significant differences in open arm entries or closed arm entries. In female rats, the
early Aripiprazole treatment resulted in a trend to a significant increase in closed arm
duration (+57%, p = 0.056). These results indicated that early APD treatment with
Aripiprazole, Olanzapine and Risperidone in the male rodent model all subsequently led to
the expression of anxiolytic-like behaviours in adulthood. In the female model, although no
significant effects of early APD treatment on anxiety-like behaviours were found in the
female animal model, analysis via ANCOVA found a trend to significant effects of Total
Distance Travelled on closed arm changes (F1,42 = 3.077, p =0.088), indicating again that
early APD treatment has stronger long-term effects on the male cohort.
Figure 2. Behavioural Effects - Anxiety (A) EPM Centre Duration (s); (B) EPM Open Part Duration (s); (C)
EPM Closed Arm Duration (s); (D) Open Field/Holeboard Centre Frequency in male Sprague-Dawley rats
treated chronically with Aripiprazole (1.0 mg/kg, t.i.d), Olanzapine (1.0 mg/kg, t.i.d), Risperidone (0.3 mg/kg,
t.i.d) or control (vehicle). Data expressed as mean ± SEM. *, p < 0.05, **, p < 0.01, ***, p < 0.001 vs. control.
Abbreviations: EPM: Elevated-Plus Maze; t.i.d.: three times daily.
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Table 2. Behaviour of Male & Female Sprague-Dawley rats treated with chronic treatment of
Aripiprazole (1.0 mg/kg, t.i.d.), Olanzapine (1.0 mg/kg, t.i.d.), Risperidone (0.3
mg/kg, t.i.d.) in the Elevated Plus Maze (EPM) tests.
Control

Aripiprazole

Olanzapine

Risperidone

1.4 ± 0.4

1.1 ± 0.4

1.0 ± 0.3

0.9 ± 0.3

Closed Arm
Entries

1.7 ± 0.3

1.5 ± 0.3

1.1 ± 0.1

1.3 ± 0.2

Closed Arm
Changes

8.6 ± 1.1

9.0 ± 1.0

7.4 ± 1.0

10.9 ± 1.1

Open Arm
Duration (s)

19.5 ± 6.2

18.8 ± 5.8

13.6 ± 4.5

8.2 ± 3.3

Closed Arm
Duration (s)

284.4 ± 8.7

211.8 ±
10.3***

244.5 ± 14.1

243.7 ± 10.7*

Centre Duration
(s)

116.1 ± 6.6

189.3 ±
10.3***

161.9 ± 14.2*

168.1 ± 9.5**

Open Part
Duration
(s)

135.64 ±
8.7

208.17 ±
10.3***

175.50 ± 14.1

176.31 ±
10.7*

2.0 ± 0.8

1.6 ±0.6

3.0 ± 0.5

3.0 ± 0.8

Closed Arm
Entries

2.3 ± 0.5

2.0 ± 0.4

3.3 ± 0.5

3.2 ± 0.4

Closed Arm
Changes

10.1 ± 1.4

10.3 ± 1.0

10.8 ± 0.9

11.9 ± 1.0

Open Arm
Duration (s)

23.6 ± 9.0

14.2 ± 6.0

28.8 ± 5.8

30.1 ± 9.5

Closed Arm
Duration (s)

159.8 ±

250.3 ± 12.0

214.8 ± 10.8

226.1 ± 7.5

Male
Open Arm Entries

Female
Open Arm Entries

15

36.3
Centre Duration
(s)

Open Part
Duration
(s)

151.9 ±
13.7

155.5 ± 9.4

176.4 ± 7.0

163.8 ± 8.3

175.55 ±
14.3

169.67 ± 12.0

205.25 ± 10.8

193.91 ± 7.5

Data are expressed as mean ± SEM. * p ≤ 0.05 vs control; ** p < 0.01vs control; *** p
< 0.001 vs control.

3.3. Social Interaction
On PD86, all treatment groups and both genders underwent Social Interaction testing to
examine behavioural parameters including anxiety and social behaviours. Analysis found no
significant differences between the control and drug treatment groups across all of the
measured parameters (Table 3). The results indicate that childhood/adolescent APD treatment
in both male and female rats had no significant effects on the adult social behaviours
examined by the social interaction tests, when compared to the control group.

Table 3. Behaviour of Male & Female Sprague-Dawley rats treated with chronic treatment of
Aripiprazole (1.0 mg/kg, t.i.d.), Olanzapine (1.0 mg/kg, t.i.d.), Risperidone (0.3
mg/kg, t.i.d.) in the Social Interaction tests.
Control

Aripiprazole

Olanzapine

Risperidone

159.0 ±
13.7

140.3 ± 14.4

155.6 ± 17.7

159.5 ± 17.4

In Proximity
Duration (%)

38.3 ± 3.4

33.4 ± 3.4

37.1 ± 4.2

38.0 ± 4.1

Mean Distance
Between (cm)

12.4 ± 0.3

12.8 ± 0.4

11.1 ± 0.5

11.6 ± 0.4

Male
In Proximity
Duration (s)

Female
In Proximity
16

Duration (s)

166.9 ±
17.9

188.5 ± 7.2

212.3 ±7.9

182.2 ± 12.6

In Proximity
Duration (%)

39.7 ± 4.3

44.9 ± 1.7

50.5 ± 1.9

43.4 ± 3.0

Mean Distance
Between (cm)

12.0 ± 0.2

11.3 ± 0.2

11.5 ± 0.6

11.6 ± 0.4

Data are expressed as mean ± SEM. * p ≤ 0.05 vs control; ** p < 0.01vs control;
*** p < 0.001 vs control.

3.4. Forced Swim Test
Analyses again demonstrated that male and female rats responded differently to early APD
treatment (Table 4). Two-way ANOVAs (Gender x Treatment) revealed significant effects of
Gender on climbing duration (F1,86 = 60.582, p < 0.001), swimming duration (F1,86 = 67.758, p
< 0.001) and floating duration (F1,86 = 19.833, p < 0.001), along with a significant interaction
between the two factors on climbing duration (F3,86 = 6.929, p < 0.001), swimming duration
(F3,86 = 5.880, p < 0.01) and floating duration (F3,86 = 7.989, p < 0.001). In male rats, analysis
via ANCOVA found a trend to significant effect of Total Distance Travelled on swimming
duration (F1,46 = 3.165, p = 0.083) and a trend to significant effect of Treatment on climbing
duration (F3,46 = 3.012, p < 0.05), whilst analysis via one-way ANOVA found that early APD
treatment caused a trend towards significance on floating duration (F3,45 = 2.720, p = 0.056).
Early Olanzapine drug treatment increased climbing duration (+87%, p < 0.05) and decreased
floating duration (-21%, p < 0.05) compared with the control (Table 4). However, similar
effects were not observed in any of the other male drug treatment groups (both p > 0.05). In
female rats, analysis of data via ANCOVA found a significant effect of both Total Distance
Travelled (F1,43 = 4.839, p < 0.05) and Treatment (F3,43 = 3.477, p < 0.05) on swimming
duration, whilst analysis of climbing duration also found a significant effect of Treatment
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(F3,43 = 5.019, p < 0.01). Furthermore, one-way analysis of floating duration also found a
significant effect of early APD treatment (F3,46 = 4.428, p < 0.01) (Table 4). Early Olanzapine
drug treatment decreased climbing duration (-55%, p < 0.05), and increased floating duration
(+17%, p < 0.05) when compared to the control group. Furthermore, early Risperidone drug
treatment was found to significantly decrease swimming duration (-50%, p < 0.05) and
climbing duration (-47%, p = 0.05), and increase floating duration (+20%, p < 0.05) when
compared to the control (Table 4). These results indicate that early APD treatment has
opposing effects on locomotor activity and depressive-like behaviour in adult male and
female rats, indicating again that early APD treatment causes a gender specific response in
behavioural activity (Figure 1). Furthermore, the early Aripiprazole treatment was not found
to change locomotor activity, nor depressive-like behaviour in either the male or female
cohorts.
Figure 3. Behavioural Effects – Depressive (A) Male FST Climbing (s); (B) Female FST
Climbing (s) in Sprague-Dawley rats treated chronically with Aripiprazole (1.0 mg/kg,
t.i.d), Olanzapine (1.0 mg/kg, t.i.d), Risperidone (0.3 mg/kg, t.i.d) or control (vehicle).
Data expressed as mean ± SEM. *, p < 0.05 vs. control. Abbreviations: FST: Forced
Swim test; t.i.d.: three times daily.
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Table 4. Behaviour of Male & Female Sprague-Dawley rats treated with chronic treatment of
Aripiprazole (1.0 mg/kg, t.i.d.), Olanzapine (1.0 mg/kg, t.i.d.), Risperidone (0.3
mg/kg, t.i.d.) in the Forced Swim (FS) tests.
Control

Aripiprazole

Olanzapine

Risperidone

59.25 ± 9.2

86.9 ± 12.1

110.8 ± 18.3*

76.3 ± 9.7

9.75 ± 0.9

12.75 ± 1.9

7.3 ± 1.4

10.9 ± 2.7

231.0 ± 9.6

200.3 ± 13.0

181.9 ± 17.9*

212.8 ± 8.6

49.2 ± 7.1

40.5 ± 7.0

21.9 ± 3.8*

26.2 ± 5.3*

37.5 ± 4.7

24.5 ± 2.6

28.0 ± 5.1

18.7 ± 2.5*

213.3 ±
11.1

235.0 ± 8.5

250.1 ± 8.3*

255.1 ± 7.0*

Male
Climbing (s)

Swimming (s)

Floating (s)

Female
Climbing (s)

Swimming (s)

Floating (s)

Data are expressed as mean ± SEM. * p ≤ 0.05 vs control; ** p < 0.01vs control;
*** p < 0.001 vs control.

4. Discussion
The present study investigated the effects of childhood/adolescent treatment with
Aripiprazole, Olanzapine and Risperidone on long-term (adult) behavioural attributes in both
male and female rats. Our results provide evidence that early APD treatment causes longterm changes to locomotor, depressive-like and anxiety-like behaviours, and demonstrate that
there are gender differences in both locomotor activity and depressive-like behaviours in
response to early APD treatment.
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Our study found significant increases in numerous parameters indicative of hyper-locomotor
activity in the male rodent model between the drug treatment and control groups, across both
the open-field/holeboard and FS behavioural tests (Figure 1). Rats that received early
Risperidone treatment showed increased velocity, distance and rearing in the openfield/holeboard test, whilst rats that received early Olanzapine treatment showed increased
time spent climbing and decreased time spent floating when compared to the control. In
addition, locomotor activity of the male rat early Aripiprazole drug treatment group was
unchanged compared to the control. Although increased rearing behaviour has previously
been correlated to vertical activity and exploratory/vigilant behavioural attributes (Brenes
Sáenz et al. 2006; du Bois et al. 2008), no alterations in the number of head dips, also an
indicator of exploratory behaviour was observed. This therefore indicates the differences in
rearing activity observed may potentially be due to alterations in activity levels alone.

Thus far, animal studies investigating the effects of early, short-term treatment with APDs on
long-term locomotor activity have found differing results (Milstein et al. 2013; Shu et al.
2014; Varela et al. 2014). Milstein and colleagues (Milstein et al. 2013) investigated the
effects of early Olanzapine treatment on locomotor activity in adulthood, with no changes to
numerous parameters of the open-field test observed. Similarly, the present study found
increases in the activity levels of Olanzapine-treated animals in the FS test but not in the
Open-Field/Holeboard test, potentially due to the increased stress levels induced by the FS
testing procedure. In addition, the investigation by Shu et al (Shu et al. 2014) found that
repeated early treatment with Olanzapine and Clozapine induced a persistent inhibition of
PCP-induced hyper-locomotion in adulthood, a test commonly used to investigate motor
activity levels. However, they reported that on ‘re-habituation’ days in adulthood (when rats
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were totally drug free during the long-term drug treatment period), visible increases in
activity levels were observed. It is possible that this is due to a drug withdrawal-induced
behavioural hypersensitivity, and that the long-term antagonistic actions of drugs, such as the
administration of Olanzapine and Risperidone in adolescence, potentially cause the changes
in activity levels observed in the present study. Furthermore, concurrent with the findings of
our study, numerous studies have also found that Aripiprazole treatment does not cause any
impairments to motor activity levels (Leite et al. 2008; Biojone et al. 2011).

Along with increased locomotor activity, the aforementioned changes to behavioural
parameters in the FS test was also indicative of changes to depressive-like behaviour in both
the male and female rodent models of the present study. In the male cohort, rats that received
early Olanzapine treatment showed increased time spent climbing and decreased time spent
floating, indicative of a decrease in depressive-like behaviour (Costa et al. 2013). Conversely,
in the female cohort, significant decreases in time spent climbing and significant increases in
time spent floating were observed in both early Olanzapine and Risperidone drug treatments,
indicative of an increase in depressive-like behaviour (Costa et al. 2013).

Previous animal studies looking at the effects of APD treatment on depressive-like behaviour
in the FS test has found similar gender-dependent results to those in the present study
(Weiner et al. 2003; Sharma et al. 2015). Weiner and colleagues (Weiner et al. 2003) found
that acute treatment of adult male rodents with Olanzapine was found to decrease immobility
time (time spent floating) in response to the APD treatment, similar to the results found in the
present study. Additionally, increases in immobility time was found by Sharma and
colleagues (Sharma et al. 2015) following long-term Olanzapine treatment in adult female
rodents, observations that were also found in the present study.
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The differences in the Olanzapine, Risperidone, and Aripiprazole receptor binding profiles,
receptor occupancy levels and mechanisms of action, in particular on the DA and 5-HT
receptors, may result in the locomotor activity and depressive-like behavioural differences
across these different drug treatment groups. With high-affinity, high receptor occupancy,
partial agonist mechanism of action known to have the beneficial effects of normalizing NT
activity (Natesan et al. 2006), Aripiprazole (a partial D2 agonist) may not cause the long-term
alterations to the DA NT system seen with adolescent exposure to the potent antagonistic
effects of APDs including Olanzapine and Risperidone, and subsequently no changes to
locomotor activity. Although changes to locomotor activity-related behavioural parameters
were exhibited in the holeboard and FS tests, similar changes were not found in the EPM.
One possible explanation for this is the added parameter of height present in the EPM that
was not present in the other behavioural tests. The effects of this increased height also
potentially affect the number of open-arm entries/duration, and thus the anxiety-like
behaviour as examined below. This leads to the possibility that previously documented
differences in height and bright-space anxiety (Komada et al. 2008) effect the level of
locomotor activity in the EPM test.

Analysis of behavioural data from the male cohort of the present study also found changes to
behavioural parameters indicative of anxiolytic behaviour. Compared to the control group,
long-term increases in time spent in the open-part (open-arm plus centre duration), and
corresponding decreases in time spent in the closed-arms of the EPM were observed in all
three APD treatment groups, parameters known to be indicative of anxiolytic behaviour
(Mällo et al. 2007; Walf and Frye 2007; Komada et al. 2008; Tsujimura et al. 2008).
However, segmenting the open-part data into time spent on the open-arm and centre platform
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individually found a significant increase in time spent on the centre platform only, with no
differences between drug treatment groups in time spent on the open arms. In addition, a
trend to significant increase in centre frequency in the open field/holeboard test following
early Risperidone treatment was also found. Thus, in the present study, adolescent APD
treatment may potentially cause anxiolytic effects specifically towards bright spaces (due to
the differences in light intensity of the open part (100 lx) and closed-arms (darkness)) when
compared to the control (Figure 2), with no differences in height-anxiety between the
treatment groups and the control were found at the 60cm elevation. Further behavioural
testing such as the light/dark transition test is required however to clarify any different
aspects in anxiety-like behaviour. However, previous animal studies examining the effects of
APD treatment on anxiety-like behaviours have found differing results across treatment
groups. Whilst studies in adult rats over a short-term/acute period have found that the partial
agonist actions of Aripiprazole induced a similar increase in time spent in the open-arms and
a decrease in time spent in the closed-arms of the elevated maze (indicative of anxiolytic
effects) (Biojone et al. 2011), studies investigating the effects of treatment with Risperidone
and Haloperidol demonstrated anxiogenic effects, opposite to the effects seen in the present
study (Karl et al. 2006).

The discrepancy between the results of our study and those previous may be due to both the
differences in time between treatment and behavioural testing, and the age of the animals
undergoing treatment. Firstly, it is important to consider that whilst previous studies have
investigated the immediate effects of short-term/acute or chronic treatment in adult rats on
anxiety-related behaviours in adulthood, our study investigated the long-term effects of early
(childhood/adolescent) APD treatment on adult behaviour. Hence, changes to NT systems,
including the DA and 5-HT systems targeted by APDs, may have occurred following APD
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withdrawal in the time period between drug treatment and behavioural testing in the present
study, resulting in the differences in both depressive-like and anxiety-like behaviours.
Furthermore, the current study used a young animal treatment model compared to the adult
model of previous studies. This difference in treatment age may be critical to the different
results observed, with the antagonistic actions of Olanzapine treatment during the critical
neurodevelopmental period previously found to result in long-term alterations to NT
functioning, including the DA and 5-HT NT systems (Vinish et al. 2012; Milstein et al.
2013).

Surprisingly, our study also found gender-specific behavioural effects in response to early
APD treatment. Firstly, no anxiety-related changes were observed in adult female rats, whilst
the alterations to locomotor activity were found to be both dissimilar and to a far lesser extent
to those of the male cohort. Further comparison of activity related changes also identified that
the significant gender based difference in total distance moved (~33% greater for females)
was almost as strong as the effect of Risperidone drug treatment in the male cohort (~26%
greater for Risperidone treatment), reported previously. Also, whilst behavioural observations
indicative of changes in depressive-like behaviour were also seen in the adult female rats FS
test, early treatment with Olanzapine and Risperidone were found to induce an increase in
depressive-like behaviour in adulthood, an opposite effect to that seen in the male cohort.
Analysis of the FS test data revealed decreases in time spent climbing (s; Olanzapine
treatment) and swimming (s; Risperidone treatment), and subsequent increases in time spent
floating (s; Olanzapine and Risperidone treatment). There could be numerous reasons for the
differential effects in locomotor, anxiety and depressive-related behaviours observed between
the genders. Firstly, gender-based differences in the neurodevelopment of the DA NT system
are well-postulated, and may affect the behavioural differences observed in the present study.
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During the developmental phase, studies have found both regional and gender-based
differences in the development of the DA NT system, including differences in; striatal DA D1
and D2 receptor overproduction and elimination, DA D1 receptor densities in the nucleus
accumbens, grey and white matter overproduction and elimination and rates of myelination
(Andersen 2003; Sinclair et al. 2014). These gender-based differences in the development of
the DA NT system, combined with early APD treatment during this neurodevelopmental
window, may explain the observed gender differences in the predominately DA-related
locomotor activity changes of the present study.

Furthermore, the sex hormones testosterone and estrogen may also contribute to the gender
differences in the behavioural results observed in the present study. During adolescence,
testosterone and estrogen influence brain maturation/development in dopaminergic regions
including the striatum and prefrontal cortex, and also have a significant role in shaping the
dopaminergic signal (Andersen 2003; Purves-Tyson et al. 2012; Sinclair et al. 2014).
Previous animal studies have found that augmenting both testosterone and estrogen levels has
resulted in altered DA neurotransmission, including DA synthesis, DA receptor mRNA
expression and DA transporter levels, as well as changes in DA-related behaviours such as
locomotor activity (Purves-Tyson et al. 2012; Sinclair et al. 2014). Additionally, some
‘neuro-protective’ effects of estrogen on DA and 5-HT NT system-related behaviours have
been found, with estrogen exhibiting an ability to inhibit the DA D2 and 5-HT1A receptorinduced mediated behavioural changes in sensorimotor gating/information processing, which
are deficient in people with mental illnesses (Dunlop and Nemeroff 2007; Gogos et al. 2012).
This ability of estrogen to inhibit both DA and 5-HT related changes may account for the
differences in the predominately 5-HT-related anxiety, along with the DA and 5-HT related
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depressive-like behaviours observed between genders, however further research in this area is
needed.

It has been postulated that the physiology behind early insult drug induced hyper-locomotor
effects may be due to a drug-treatment induced long-term receptor hypersensitivity (Samaha
et al. 2007; Shu et al. 2014). This phenomenon reports that continuous APD treatment (with
high affinities for DA receptors) may cause an up-regulation of DA receptors, and thus upon
APD withdrawal, enhance dopaminergic signalling in brain regions including the nucleus
accumbens, hippocampus and striatum, previously observed in animals exhibiting hyperlocomotor activity (Kelly et al. 1975; Kusljic et al. 2003; Miyakawa et al. 2003; Seo et al.
2008; Beaulieu and Gainetdinov 2011). The potent antagonist actions of chronic Risperidone
and Olanzapine APD treatment on the DA D2 receptors during the critical
childhood/adolescent neurodevelopmental period in the present study may have resulted in a
long-term DA receptor and consequent DA synthesis up-regulation, enhancing the
dopaminergic signal along these brain regions previously heavily implicated in locomotor
activity.

Furthermore, the antagonistic actions of Olanzapine and Risperidone on the 5-HT2A and 5HT2C receptors resulting in decreases in 5-HT projections may also result in similar long-term
alterations to dopaminergic signalling and locomotor activity. Previous studies have found
strong links between the antagonism of 5-HT2 receptors and enhanced locomotor activity
(Kusljic et al. 2003; Seo et al. 2008), potentially due to the negative correlation between 5HT and DA functioning. In such cases, a deficiency in 5-HT projections leads to a
disinhibition of DA signalling, and thus enhanced DA signal (Kusljic et al. 2003; Seo et al.
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2008). Similarly, the antagonistic actions of Olanzapine and Risperidone on the 5-HT2A, 5HT2C and DA D2 receptors, resulting in the aforementioned long-term alterations in
signalling, have also been correlated to anxiolytic and decreased depressive-like behaviours
(Mora et al. 1997; Andersen and Navalta 2004; Karl et al. 2006; Dunlop and Nemeroff 2007;
Seo et al. 2008; de Oliveira et al. 2009; Biojone et al. 2011). Previous studies have
demonstrated that repeated antagonism of the 5-HT2 receptors (both 5-HT2A and 5-HT2C)
have been found to result in a down regulation of both the number and sensitivity of 5-HT2
receptors (Mora et al. 1997), resulting in a long-term deficiency in serotonergic signalling,
correlated with anxiolytic- and decreased depressive-like behavioural effects. Long-term
APD use resulting in the up-regulation and hypersensitivity of DA receptors and thus
enhanced dopaminergic signalling may also play a role, with enhanced DA signalling in brain
regions including the ventral tegmental area, prefrontal cortex and nucleus accumbens
correlated with the anxiolytic- and decreased depressive-like behavioural effects exhibited in
the present study (Karl et al. 2006; de Oliveira et al. 2009; Biojone et al. 2011).
Finally, despite a high affinity partial agonist mechanism of action on the DA D2 and 5-HT1A
receptors (Shapiro et al. 2003), adolescent Aripiprazole APD treatment was also found to
elicit anxiolytic-like effects in adult rats. Such effects on anxiety, with no differences in
locomotor activity or depressive-like behaviours, it suggests a potential vital role of the 5HT2A and 5-HT2C receptors in anxiety-like behaviour alone, as Aripiprazole is known to have
an antagonistic mechanism of action on the former, and a slightly lower affinity for the latter
5-HT receptor subtypes (Shapiro et al. 2003). Since Olanzapine and Risperidone also have a
similar antagonistic and agonistic mechanisms of action on the 5-HT2A and 5-HT2C receptors
respectively and exhibit similar effects, this may provide further evidence for the potentially
crucial role that mediating these individual receptor subtypes may have in regulating anxiety,
although further studies investigating this is necessary.
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With clear long-term depressive-like, anxiety behavioural alterations found in the present
study, minor alterations to current methods, along with additional investigations will provide
further insight into the effects of childhood/adolescent APD use on behavioural attributes.
Firstly, altering the social interaction protocol in order to pair naïve age and sex-matched
animals may reveal some potential differences in social behaviour that the current method of
sex and gender-matched animals may have occluded. Secondly, additional behavioural
testing investigating the effects of early APD use on other behavioural parameters including
cognitive abilities would be helpful in assessing any potential issues with short and long-term
memory in the adult rat, whilst also investigating the effects of other commonly used APDs
including Clozapine would also increase the scope of the current investigation. Furthermore,
it may also be of benefit for supplementary investigations to be completed on the effects of
early APD treatment in disease animal models of mental illness e.g. schizophrenia. Whilst the
use of a standard rat strain in the present study is appropriate and clinically relevant due to an
inability to investigate in a single animal model for the multiple illnesses (such as
schizophrenia, bipolar disorder, autism, ADHD, Tourette’s disorder, anxiety disorder,
borderline personality disorder and even hemiplegia) APDs are used to treat (Olfson et al.
2010; Memarzia et al. 2014; Schneider et al. 2014), and the reported inadvertent exposure of
healthy adolescent brains to APDs due to difficulties in diagnosis at a young age (Andersen
and Navalta 2011; Zuddas et al. 2011), increasing the scope of the study to investigate the
long-term effects early APD use has on individual illnesses will no doubt be beneficial.

In conclusion, this study indicates that early APD treatment results in long-term changes on
locomotor, depressive-like and anxiety-like behaviours in adult rats. In addition, behavioural
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differences between genders were also observed in response to early APD treatment.
Potential detrimental long-term behavioural changes following early APD treatment may
outweigh the initial benefits of childhood/adolescent APD prescription and use. Whilst
previous clinical studies have shown gender based differences in APD treatment effects
(Ratzoni et al. 2002), our study indicates that these differential effects may not only extend to
behavioural attributes but also into adulthood. Hence, careful consideration of both the
pharmacology of the APD being prescribed along with the gender of the child may be crucial
to decrease any potential long-term effects, including alterations to activity, anxiety or
depressive-like behaviours. Further research is required in order to explore the potential
physiological reasons behind the behavioural differences found across both treatment groups
and genders, which has potentially resulted in the observed effects. Investigations into
potential alterations to both the DA and 5-HT NT systems in key brain areas would provide
further evidence of these potential detrimental long-term neurotransmitter alterations.
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